Patents Represented by Attorney, Agent or Law Firm James J. Kelley
-
Patent number: 7318923Abstract: Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.Type: GrantFiled: April 26, 2002Date of Patent: January 15, 2008Assignee: Eli Lilly and CompanyInventors: Naoya Tsurushita, Maximiliano J. Vasquez
-
Patent number: 6617343Abstract: A compound of formula l: wherein, R1, R2 and R3 independently represent hydrogen, alkyl, alkenyl, alkynyl, aryl, or aralkyl groups having 1 to 8 carbon atoms; X represents an alkoxyalkyl, alkoxyaryl, alkoxyalkylaryl, aralkylalkoxy, or alkoxyalkylheterocycle; or a pharmaceutically acceptable salt or prodrug thereof.Type: GrantFiled: May 7, 2002Date of Patent: September 9, 2003Assignee: Eli Lilly and CompanyInventor: Samuel James Dominianni
-
Patent number: 6531448Abstract: The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.Type: GrantFiled: December 21, 1998Date of Patent: March 11, 2003Assignee: Eli Lilly and CompanyInventor: Mark Laurence Brader
-
Patent number: 6444641Abstract: Fatty acid-acylated insulin analogs are soluble at moderately acidic pH and provide long-acting basal control of glucose levels. In such a molecule, the insulin analog portion comprises an insulin A-chain, or an analog thereof, properly cross-linked to an analog of the insulin B-chain, wherein the &egr;-amino group of a Lys residue at either positions 28 or 29 of the B-chain analog is acylated with a fatty acid. The insulin analog portion of the molecules comprises an A-chain of insulin, or an analog thereof, with an optional Arg at position 0, properly cross-linked to a B-chain analog that includes Arg at positions 31 and 32.Type: GrantFiled: July 7, 2000Date of Patent: September 3, 2002Assignee: Eli Lilly CompanyInventor: David Benjamin Flora
-
Patent number: 6335316Abstract: The invention relates to a method of administering a fatty acid-acylated insulin or insulin analog by inhalation, a method for treating diabetes by administering a fatty acid-acylated insulin or insulin analog by inhalation, and a method for treating hyperglycemia by administering a fatty acid-acylated insulin or insulin analog by inhalation.Type: GrantFiled: March 10, 2000Date of Patent: January 1, 2002Assignee: Eli Lilly and CompanyInventors: Benjamin Lee Hughes, Ronald Keith Wolff
-
Patent number: 6277819Abstract: This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.Type: GrantFiled: August 21, 1997Date of Patent: August 21, 2001Assignee: Eli Lilly and CompanyInventor: Suad Efendic
-
Patent number: 6268335Abstract: The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for parenteral delivery or other means of delivery, to a patient for extended control of blood glucose levels. More particularly, the present invention relates to compositions comprised of an acylated protein complexed with zinc, protamine, and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that compositions of such acylated proteins have therapeutically superior subcutaneous release pharmacokinetics, and more extended and flatter glucodynamics, than presently available commercial preparations of NPH insulin.Type: GrantFiled: October 22, 1998Date of Patent: July 31, 2001Assignee: Eli Lilly and CompanyInventor: Mark Laurence Brader
-
Patent number: 6121282Abstract: This invention provides 1,2,3,4-tetrahydroisoquinoline compounds and their pharmaceuticallyacceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.Type: GrantFiled: December 18, 1998Date of Patent: September 19, 2000Assignee: Eli Lilly and CompanyInventors: Samuel James Dominianni, William Harlan Gritton
-
Patent number: 6051551Abstract: The invention relates to a method of administering a fatty acid-acylated insulin or insulin analog by inhalation, a method for treating diabetes by administering a fatty acid-acylated insulin or insulin analog by inhalation, and a method for treating hyperglycemia by administering a fatty acid-acylated insulin or insulin analog by inhalation.Type: GrantFiled: October 29, 1998Date of Patent: April 18, 2000Assignee: Eli Lilly and CompanyInventors: Benjamin Lee Hughes, Ronald Keith Wolff
-
Patent number: 5922678Abstract: This invention describes methods of treating or preventing diabetes in obese type II diabetic patients. Specifically, methods of treating obese type II diabetics with varying levels of endogenous circulating leptin are claimed.Type: GrantFiled: March 24, 1998Date of Patent: July 13, 1999Assignee: Eli Lilly and CompanyInventor: Thomas Wesley Stephens
-
Patent number: 5922675Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to a monomeric insulin analog wherein the A chain is the naturally occurring sequence of the human insulin A chain and the B chain is modified at either position B28 and B29 or both. The analog is mono-acylated at the N-terminal of the A chain or B chain or at the lysine. The acylated insulin analogs have an extended duration of action.Type: GrantFiled: November 26, 1997Date of Patent: July 13, 1999Assignee: Eli Lilly and CompanyInventors: Jeffrey C. Baker, Jose M. Hanquier
-
Patent number: 5840517Abstract: The present invention is directed to an improved process for preparing in high yield an obesity protein analog using a dipeptidylaminopeptidase isolated from the slime mold, Dictyostelium discoideum.Type: GrantFiled: March 24, 1997Date of Patent: November 24, 1998Assignee: Eli Lilly and CompanyInventors: Paul Robert Atkinson, Lisa Kay Foster, Thomas Charles Furman, Warren Cameron MacKellar
-
Patent number: 5831017Abstract: The present invention provides novel compounds, which comprise an obesity protein analog complexed with a divalent metal cation, pharmaceutical formulations thereof, and methods of using such compounds for treating obesity, and disorders associated with obesity such as diabetes, cardiovascular disease and cancer.Type: GrantFiled: January 24, 1997Date of Patent: November 3, 1998Assignee: Eli Lilly and CompanyInventor: James Arthur Hoffmann